SciSparc is no longer the operating home of its own cannabinoid pipeline. In October of last year the Israeli parent dropped the clinical programs into NeuroThera Labs, a Toronto-listed vehicle, and the residual Nasdaq claim now prices as a cheap holdco around that stake, a shrinking hemp-oil catalog, and a stack of unrelated endoscope and agentic-software announcements. Year-end cash sat near $5 million. The equity closed mid-September near $5 a share, implying a capitalization of about $3 million. That gap is the entire debate: either the market is ignoring a NeuroThera mark that management later described as about C$30 million, or the market is correctly treating the cash as already spoken for by burn, convertibles, and another year of reverse-split finance.
The financial year that produced that cash balance also produced a $12 million net loss and a $6 million impairment on loans to AutoMax Motors after the automotive merger died and AutoMax entered court proceedings. Auditors left a going concern paragraph on the annual statements. Nasdaq had already flagged the mid-year equity deficit and later restored only conditional compliance off the year-end filing. A nine-share reverse split in early March followed an earlier twenty-one-share reverse split. A convertible note facility of up to $10 million opened in February at a ten percent original-issue discount. Clinical news is real, but it now prints under the NeuroThera letterhead.
The next stretch of months resolves whether SciSparc is a mispriced claim on two mid-stage cannabinoid studies or a holdco that keeps issuing paper to stay listed. SCI-110 has opened Phase IIb sites at Yale, Hannover, and Tel Aviv after a Phase IIa print that showed a twenty-one percent average tic reduction. SCI-210 has enrolled about half of a planned sixty-child autism study at Soroka. Neither readout is funded by the parent's current market value. The question is whether the NeuroThera stake can be monetized before the next Nasdaq equity test and the next convertible draw.